IL259394B - Reliable prodrugs in pharmaceutical compositions - Google Patents

Reliable prodrugs in pharmaceutical compositions

Info

Publication number
IL259394B
IL259394B IL259394A IL25939418A IL259394B IL 259394 B IL259394 B IL 259394B IL 259394 A IL259394 A IL 259394A IL 25939418 A IL25939418 A IL 25939418A IL 259394 B IL259394 B IL 259394B
Authority
IL
Israel
Prior art keywords
pharmaceutical compounds
amine prodrugs
prodrugs
amine
pharmaceutical
Prior art date
Application number
IL259394A
Other languages
English (en)
Hebrew (he)
Other versions
IL259394A (en
Inventor
Anthony Marfat
Original Assignee
Biohaven Pharm Holding Co Ltd
Anthony Marfat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd, Anthony Marfat filed Critical Biohaven Pharm Holding Co Ltd
Publication of IL259394A publication Critical patent/IL259394A/en
Publication of IL259394B publication Critical patent/IL259394B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539Five-membered rings
    • C07F9/6541Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL259394A 2015-11-19 2018-05-16 Reliable prodrugs in pharmaceutical compositions IL259394B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562257533P 2015-11-19 2015-11-19
PCT/US2016/062400 WO2017087594A1 (en) 2015-11-19 2016-11-17 Amine prodrugs of pharmaceutical compounds

Publications (2)

Publication Number Publication Date
IL259394A IL259394A (en) 2018-07-31
IL259394B true IL259394B (en) 2022-04-01

Family

ID=58717793

Family Applications (1)

Application Number Title Priority Date Filing Date
IL259394A IL259394B (en) 2015-11-19 2018-05-16 Reliable prodrugs in pharmaceutical compositions

Country Status (8)

Country Link
US (2) US20180318268A1 (enExample)
EP (1) EP3377111B1 (enExample)
JP (1) JP7110094B2 (enExample)
KR (1) KR20180084049A (enExample)
ES (1) ES2969792T3 (enExample)
IL (1) IL259394B (enExample)
SG (2) SG11201803645PA (enExample)
WO (1) WO2017087594A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12295942B2 (en) 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
BR112017018832B1 (pt) 2015-03-03 2023-12-26 Biohaven Pharmaceutical Holding Company Ltd Profármacos de riluzol e seu uso e composição
US12029731B2 (en) 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
US20250049748A1 (en) * 2021-12-16 2025-02-13 Terran Biosciences Inc. Analogs of 4-bromo-2,5-dimethoxyphenethylamine
WO2023141636A1 (en) * 2022-01-24 2023-07-27 Terran Biosciences Inc. Prodrugs of 2-bromo-lsd (2-bromolysergic acid diethylamide)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
WO2004045601A1 (en) 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US20040176430A1 (en) * 2002-11-21 2004-09-09 Jeffrey Sterling Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
US7101912B2 (en) * 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
AR051475A1 (es) * 2004-11-05 2007-01-17 Merck & Co Inc Procedimiento para acido{3- [2 (r) -[(1r) - 1-[ 3,5- bis( trifluorometil)- fenil] etoxi] -3 (s) - (4- fluorfenil) morfolin -4- il]metil -5-oxo-4,5-dihidro- [1,2,4]-triazol-1-il} fosfonico
WO2007022073A2 (en) * 2005-08-12 2007-02-22 Merck & Co., Inc. Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
US20090075915A1 (en) * 2007-09-17 2009-03-19 In Jong Kim 6,11-bicyclolides: bridged biaryl macrolide derivatives
US8106209B2 (en) * 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
US20130030359A1 (en) * 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US8937151B2 (en) * 2010-03-04 2015-01-20 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
US8969337B2 (en) * 2011-12-15 2015-03-03 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
WO2013167993A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
ES2675314T3 (es) * 2012-06-11 2018-07-10 Bristol-Myers Squibb Company Profármacos de ácido fosforamídico de 5-[5-fenil-4-(piridin-2-ilmetilamino) quinazolin-2-il] piridin-3-sulfonamida
US20140105921A1 (en) * 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors

Also Published As

Publication number Publication date
EP3377111B1 (en) 2023-11-29
EP3377111A4 (en) 2019-11-13
US20180318268A1 (en) 2018-11-08
IL259394A (en) 2018-07-31
EP3377111A1 (en) 2018-09-26
US20190365721A1 (en) 2019-12-05
ES2969792T3 (es) 2024-05-22
SG10202112588PA (en) 2021-12-30
US11083711B2 (en) 2021-08-10
SG11201803645PA (en) 2018-06-28
KR20180084049A (ko) 2018-07-24
JP2019501877A (ja) 2019-01-24
JP7110094B2 (ja) 2022-08-01
WO2017087594A1 (en) 2017-05-26

Similar Documents

Publication Publication Date Title
IL266017A (en) Pharmaceutical compounds
IL258213B (en) Pharmaceutical compounds
GB201612092D0 (en) Pharmaceutical compounds
GB201511790D0 (en) Pharmaceutical compound
GB201504675D0 (en) Pharmaceutical compounds
GB201506658D0 (en) Pharmaceutical compounds
GB201617758D0 (en) Pharmaceutical compounds
ZA201900540B (en) Pharmaceutical compounds
GB201519352D0 (en) Pharmaceutical compounds
GB201506660D0 (en) Pharmaceutical compounds
IL258246A (en) Pharmaceutical compounds
GB201617454D0 (en) Pharmaceutical compounds
GB201617627D0 (en) Pharmaceutical compounds
GB201612095D0 (en) Pharmaceutical compounds
GB201506933D0 (en) Pharmaceutical compounds
GB201502567D0 (en) Pharmaceutical compounds
GB201516411D0 (en) Pharmaceutical compound
IL259394B (en) Reliable prodrugs in pharmaceutical compositions
GB201617871D0 (en) Pharmaceutical compounds
SG11201708818VA (en) Pharmaceutical compound
IL259425B (en) Compounds for medical applications
GB201517451D0 (en) Pharmaceutical compounds
GB201614037D0 (en) Pharmaceutical compounds
SG11201708817XA (en) Pharmaceutical compound
GB201602871D0 (en) Pharmaceutical compounds